# US 2023/0324358 A1 · Therapeutic drug for lipid-peroxidation-induced diseases and screening method for therapeutic drugs for lipid-peroxidation-induced diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0324358 A1
- Document ID: US20230324358A1
- Status: Published application
- Kind: A1
- Application number: 17/979,453
- Filed: 2022-11-02
- Published: 2023-10-12
- Earliest claimed: 2020-01-03
- Assignees: Ken-ichi YAMADA; Fuso Pharmaceutical Industries, Ltd.
- Applicants: Fuso Pharmaceutical Industries, Ltd.
- Inventors: Ken-ichi YAMADA; Saki SHINTO; Tomomi IDE; Keiichi YAMAMOTO
- Web page: https://patentgrep.com/patent/US20230324358A1

## CPC

- G01N 33/15: Medicinal preparations {; Physical properties thereof, e.g. dissolubility}
- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/245: Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K31/60)
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C01G 49/14: Sulfates {(C01G49/0018 takes precedence)}
- C07C 57/00: Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C12N 5/067: {Hepatocytes}
- C40B 20/08: Direct analysis of the library members per se by physical methods, e.g. spectroscopy
- G01N 33/52: Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper {and including single- and multilayer analytical elements (immunological elements G01N33/54386; involving labelled immunochemicals G01N33/58; for haemoglobin or occult blood G01N33/72)}
- G01N 33/533: with fluorescent label
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N 2001/027: {field kits / quick test kits}
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C01G: COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F (metal hydrides {monoborane, diborane or addition complexes thereof} C01B6/00; salts of oxyacids of halogens C01B11/00; peroxides, salts or peroxyacids C01B15/00; thiosulfates, dithionites, polythionates C01B17/64; compounds containing selenium, or tellurium C01B19/00; binary compounds of nitrogen with metals C01B21/06; azides C01B21/08; {compounds containing nitrogen, other non-metals and metal C01B21/082}; metal amides C01B21/092; nitrites C01B21/50; {compounds of noble gases C01B23/0005}; phosphides C01B25/08; salts of oxyacids of phosphorus C01B25/16; carbides C01B32/90; compounds containing silicon C01B33/00; compounds containing boron C01B35/00; compounds having molecular sieve properties but not having base-exchange properties C01B37/00; compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites, C01B39/00; cyanides C01C3/08; salts of cyanamide C01C3/16; thiocyanates C01C3/20)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)

## Abstract

The present invention provides: an assay method that uses a compound represented by formula (I) as a fluorescent probe molecule and that is for detecting the lipid peroxidation suppression activity of a test compound; an assay kit that uses the assay method; a screening method that uses the assay method; and a pharmaceutical composition that is for the treatment, etc. of diseases (such as age-related macular degeneration) that are induced by lipid peroxidation reactions.

## Claims

### Claim 1

An assay kit for detecting lipid peroxidation inhibitory activity of a test compound, comprising:
a compound represented by formula (I):
a cultured cell, and
at least one compound selected from the group consisting of arachidonic acid and tert-butyl hydroperoxide in a buffer.

### Claim 2 (depends on 1)

The assay kit according to claim 1, wherein the cultured cell is a human hepatoma-derived HepG2 cell.

### Claim 3 (depends on 1)

The assay kit according to claim 1, further comprising a package insert showing an activity value of a compound having lipid peroxidation inhibitory activity.

### Claim 4 (depends on 1)

An assay kit comprising any two or more of the assay kits according to claim 1.

### Claim 5 (depends on 1)

An assay method for measuring lipid peroxidation inhibitory activity, comprising:
i) providing the assay kit according to claim 1;
ii) adding a test compound;
iii) measuring fluorescence; and
iv) determining an activity value of the test compound from the result of measuring the fluorescence.

### Claim 6 (depends on 5)

The assay method according to claim 5, wherein providing the assay kid comprises:
preparing the buffer containing the compound represented by formula (I) and the cultured cell; and
adding the at least one compound selected from the group consisting of arachidonic acid and tert-butyl hydroperoxide.

### Claim 7 (depends on 5)

The assay method according to claim 5, further comprising
comparing the activity value of the test compound from the result of measuring the fluorescence with an activity value of a compound serving as an indicator of lipid peroxidation inhibitory activity.

### Claim 8 (depends on 5)

The assay method according to claim 5, wherein the assay method is performed with a microwell plate.
